Huntsville, Ala. March 21, 2019 – iCubate®, a provider of molecular diagnostic solutions for infectious disease detection, hosted a panel presentation at the South Central Association of Clinical Microbiology (SCACM) meeting in Sandusky, Ohio.
The presentation titled, “A Clinical Perspective of the iCubate® Solution for Bloodstream Infection” was led by Paul A. Granato, PhD, DABMM, FAAM, director of microbiology at the Laboratory Alliance of Central New York in Syracuse, New York and Matthew Conover, PhD, molecular diagnostic assay developer at iCubate. Well attended by an engaged audience of clinical microbiologists from Ohio, Kentucky, Minnesota, Wisconsin, Indiana, Illinois, West Virginia and Michigan, Drs. Granato and Conover presented clinical and analytical data from the company’s bloodstream infection detection assays.
A key point of the presentation was the critical importance of rapid, accurate results when detecting bloodstream infection (BSI). BSI and subsequent sepsis is now the nation’s 10th leading cause of death with treatment costs over $16 billion annually.
iCubate’s platform and assays detecting gram-positive cocci (iC-GPC Assay™) and gram-negative rods (iC-GN Assay™) provide rapid identification of the most common bloodstream pathogens and clinically relevant antibiotic resistance markers to help guide antimicrobial therapy.
“With assays detecting gram-positive and gram-negative pathogens, iCubate offers care providers a complete package for improved patient care and outcomes. Multiple opinions from SCACM attendees confirmed that iCubate is on the right track with solutions for clinical labs,” said Dr. Conover.
With the goal of providing accurate diagnostic results for better patient care, high performance assays were the first priority of the iCubate development team. The data presented at SCACM illustrated that this goal was met.
“The iCubate clinical data are strong in comparison with industry standards. The performance of the assays, coupled with the ease of use of the overall platform, makes iCubate a viable option for small and large clinical laboratories”, Granato continued.
The iC-GPC Assay™ has been cleared for clinical laboratory use by the FDA and the iC-GN Assay™ is currently under regulatory review. iCubate’s pipeline of infectious disease detection products include the iCubate Mycobacterium Assay, the iCubate Gastrointestinal Assay and the iCubate Respiratory Assay.
About iCubate: iCubate® is a molecular diagnostic company committed to providing rapid, accurate and affordable syndromic testing for infectious diseases to clinical laboratories, leading to better care, sooner. The iCubate System is an all-in-one, easy to use multiplex PCR molecular diagnostics platform that detects and identifies bacterial and viral pathogens as well as antibiotic resistance markers for actionable results when clinicians need them. To learn more about iCubate, visit iCubate.com.